M.D. ANDERSON WILL COMPARE KYTRIL AND ZOFRAN IN HEAD-TO-HEAD TRIAL
Executive Summary
M.D. ANDERSON WILL COMPARE KYTRIL AND ZOFRAN IN HEAD-TO-HEAD TRIAL of the two anti-emetics expected to begin this summer. The M.D. Anderson Cancer Center, one of the largest purchasers of Glaxo's Zofran (ondansetron), added SmithKline Beecham's Kytril (granisetron) to its formulary in mid-April "for a period of time" to evaluate Kytril's effectiveness and monitor its use. SB introduced Kytril March 23.